The Enasidenib Market is expected to register at a highest CAGR   during the forecast period. Enasidenib is a drug that targets a gene mutation called IDH2 that affects the bone marrow. A mutation in the IDH2 gene inhibits young blood cells from maturing into healthy adult blood cells, resulting in acute myeloid leukaemia symptoms. AML is a form of blood cancer, that starts in the bone marrow and spreads throughout the body. The illness spreads quickly to other sections of the body.

In the vast majority of cases, patients with AML experience relapses.

Since the COVID-19 virus outbreak in December 2019, the disease spread to almost every country around the globe with the World Health Organization, declaring it a public health emergency. The global impacts of the coronavirus disease (COVID-19) had significantly affect the Enasidenib market in 2020.  

Enasidenib is a drug that is used to treat adults with acute myeloid leukaemia (AML), who has an IDH2 mutation. When AML has affected again or has not improved after previous treatment, this medication is given.  

Enasidenib damages blood cells and, if not treated, can be fatal. This condition can happen anywhere between 10 days to 5 months after starting Enasidenib.

The revenue share of the Enasidenib market will increase as the healthcare industry develops. The market will expand as people are becoming more aware of health issues, and better facilities are beingavailable. As a result, the market in developed regions will grow dramatically.

Symptoms of Enasidenib syndrome include fever, cough, trouble breathing, bone pain, rapid weight gain, or swelling in your arms, legs, underarms, groin, or neck.

In August 2017, Enasidenibis was approved by the U.S. Food and Drug Administration   (FDA) for the treatment of geriatric patients with relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase-2 mutation as detected by an FDA-approved test  .and IDHIFA wasalso approved in Australia and Canada in August 2017.  

In August 2020, Bristol yerssquibb updated on Phase 3 IDHENTIFY trial in patients with relapsed or refactory acute myeloid leukemia.

Market Coverage

• The market number available for – 2020-2027
• Base year- 2020
• Forecast period- 2021-2027
• Regions Covered- Globally
• Competitive Landscape: Celgene Corporation ,  Agios Pharmaceuticals  among others. 

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How COVID-19 impacted the market?
• Deviation from the pre-COVID-19 forecast
• Most affected region and segment
• Who is the leader in the market?

Enasidenib Market By Type:

o 50mg

o 100mg

Enasidenib Market By Application:

o Hospital

o Pharmacy

Enasidenib Market by Region